ID: MRFR/MED/4427-HCR | February 2021 | Region: Global | 100 Pages
Table Of Content
1. Report Prologue
2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
5. Market Factor Analysis
5.1 Porterβs Five Forces Analysis
5.1.1 Bargaining Power Of Suppliers
5.1.2 Bargaining Power Of Buyers
5.1.3 Threat Of New Entrants
5.1.4 Threat Of Substitutes
5.1.5 Intensity Of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
6. Global Tachycardia Market, By Type
6.1 Introduction
6.2 Atrial Fibrillation
6.2.1 Market Estimates & Forecast, 2020β2027
6.3 Atrial Flutter
6.3.1 Market Estimates & Forecast, 2020β2027
6.4 Supraventricular Tachycardia
6.4.1 Market Estimates & Forecast, 2020β2027
6.5 Ventricular Tachycardia
6.5.1 Market Estimates & Forecast, 2020β2027
6.6 Ventricular Fibrillation
6.6.1 Market Estimates & Forecast, 2020β2027
6.7 Tachy-Brady Syndrome
6.7.1 Market Estimates & Forecast, 2020β2027
7. Global Tachycardia Market, By Treatment
7.1 Introduction
7.2 Vagal Maneuvers
7.2.1 Market Estimates & Forecast, 2020β2027
7.3 Medications
7.3.1 Market Estimates & Forecast, 2020β2027
7.4 Cardioversion
7.4.1 Market Estimates & Forecast, 2020β2027
8. Global Tachycardia Market, By Diagnosis
8.1 Introduction
8.2 Imaging Tests
8.2.1 Echocardiogram
8.2.2 MRI
8.2.3 CT Scan
8.2.4 Coronary Angiogram
8.2.5 Chest X-Ray
8.2.6 Market Estimates & Forecast, 2020β2027
8.3 Electrocardiogram (ECG)
8.3.1 Market Estimates & Forecast, 2020β2027
8.4 Stress Test
8.4.1 Market Estimates & Forecast, 2020β2027
9. Global Tachycardia Market, By End-User
9.1 Introduction
9.2 Hospitals & Clinics
9.2.1 Market Estimates & Forecast, 2020β2027
9.3 Specialty Centers
9.3.1 Market Estimates & Forecast, 2020β2027
9.4 Ambulatory Surgical Centers
9.4.1 Market Estimates & Forecast, 2020β2027
10 Global Tachycardia Market, By Region
10.1 Introduction
10.2 Americas
10.2.1 North America
10.2.1.1 U.S.
10.2.1.2 Canada
10.2.2 South America
10.3 Europe
10.3.1 Western Europe
10.3.1.1 Germany
10.3.1.2 France
10.3.1.3 U.K.
10.3.1.4 Italy
10.3.1.5 Spain
10.3.1.6 Rest Of Western Europe
10.3.2 Eastern Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 Republic Of Korea
10.4.6 Rest Of Asia Pacific
10.5 The Middle East & Africa
10.5.1 United Arab Emirates
10.5.2 Saudi Arabia
10.5.3 Oman
10.5.4 Kuwait
10.5.5 Qatar
10.5.6 Rest Of The Middle East & Africa
11 Company Landscape
11.1 Introduction
11.2 Market Share Analysis
11.3 Key Development & Strategies
11.3.1 Key Developments
12 Company Profiles
12.1 Abbott Laboratories
12.1.1 Company Overview
12.1.2 Product Overview
12.1.3 Financials
12.1.4 SWOT Analysis
12.2 Terumo Corporation
12.2.1 Company Overview
12.2.2 Product Overview
12.2.3 Financial Overview
12.2.4 Key Developments
12.2.5 SWOT Analysis
12.3 Cardinal Health, Inc.
12.3.1 Company Overview
12.3.2 Product Overview
12.3.3 Financial Overview
12.3.4 Key Development
12.3.5 SWOT Analysis
12.4 Cardiva Medical, Inc.
12.4.1 Company Overview
11.4.2 Product/Business Segment Overview
11.4.3 Financial Overview
11.4.4 Key Development
11.4.5 SWOT Analysis
12.5 Medtronic PLC
12.5.1 Company Overview
12.5.2 Product Overview
12.5.3 Financial Overview
12.5.4 Key Developments
12.6 Morris Innovative, Inc.
12.6.1 Company Overview
12.6.2 Product Overview
12.6.3 Financial Overview
12.6.4 Key Developments
12.7 Essential Medical, Inc.
12.7.1 Overview
12.7.2 Product Overview
12.7.3 Financials
12.7.4 Key Developments
12.7.5 SWOT Analysis
12.8 Others
13 MRFR Conclusion
13.1 Key Findings
13.1.1 From CEOβs View Point
13.1.2 Unmet Needs Of The Market
13.2 Key Companies To Watch
13.3 Prediction Of The Pharmaceutical Industry
14 Appendix
LIST OF TABLES
Table 1 Tachycardia Industry Synopsis, 2020β2027
Table 2 Global Tachycardia Market Estimates & Forecast, 2020β2027, (USD Million)
Table 3 Global Tachycardia Market, By Region, 2020β2027, (USD Million)
Table 5 Global Tachycardia Market, By Type, 2020β2027, (USD Million)
Table 6 Global Tachycardia Market, By Treatment, 2020β2027, (USD Million)
Table 7 Global Tachycardia Market, By Diagnosis, 2020β2027, (USD Million)
Table 8 Global Tachycardia Market, By End-User, 2020β2027, (USD Million)
Table 9 North America Tachycardia Market, By Type, 2020β2027, (USD Million)
Table 10 North America Tachycardia Market, By Treatment, 2020β2027, (USD Million)
Table 11 North America Tachycardia Market, By Diagnosis, 2020β2027, (USD Million)
Table 12 North America Tachycardia Market, By End-User, 2020β2027, (USD Million)
Table 13 U.S. Tachycardia Market, By Type, 2020β2027, (USD Million)
Table 14 U.S. Tachycardia Market, By Treatment, 2020β2027, (USD Million)
Table 15 U.S. Tachycardia Market, By Diagnosis, 2020β2027, (USD Million)
Table 16 U.S. Tachycardia Market, By End-User, 2020β2027, (USD Million)
Table 17 Canada Tachycardia Market, By Type, 2020β2027, (USD Million)
Table 18 Canada Tachycardia Market, By Treatment, 2020β2027, (USD Million)
Table 19 Canada Tachycardia Market, By Diagnosis, 2020β2027, (USD Million)
Table 20 Canada Tachycardia Market, By End-User, 2020β2027, (USD Million)
Table 21 South America Tachycardia Market, By Type, 2020β2027, (USD Million)
Table 22 South America Tachycardia Market, By Treatment, 2020β2027, (USD Million)
Table 23 South America Tachycardia Market, By Diagnosis, 2020β2027, (USD Million)
Table 24 South America Tachycardia Market, By End-User, 2020β2027, (USD Million)
Table 25 Europe Tachycardia Market, By Type, 2020β2027, (USD Million)
Table 26 Europe Tachycardia Market, By Treatment, 2020β2027, (USD Million)
Table 27 Europe Tachycardia Market, By Diagnosis, 2020β2027, (USD Million)
Table 28 Europe Tachycardia Market, By End-User, 2020β2027, (USD Million)
Table 29 Western Europe Tachycardia Market, By Type, 2020β2027, (USD Million)
Table 30 Western Europe Tachycardia Market, By Treatment, 2020β2027, (USD Million)
Table 31 Western Europe Tachycardia Market, By Diagnosis, 2020β2027, (USD Million)
Table 32 Western Europe Tachycardia Market, By End-User, 2020β2027, (USD Million)
Table 33 Eastern Europe Tachycardia Market, By Type, 2020β2027, (USD Million)
Table 34 Eastern Europe Tachycardia Market, By Treatment, 2020β2027, (USD Million)
Table 35 Eastern Europe Tachycardia Market, By Diagnosis, 2020β2027, (USD Million)
Table 36 Eastern Europe Tachycardia Market, By End-User, 2020β2027, (USD Million)
Table 37 Asia Pacific Tachycardia Market, By Type, 2020β2027, (USD Million)
Table 38 Asia Pacific Tachycardia Market, By Treatment, 2020β2027, (USD Million)
Table 39 Asia Pacific Tachycardia Market, By Diagnosis, 2020β2027, (USD Million)
Table 40 Asia Pacific Tachycardia Market, By End-User, 2020β2027, (USD Million)
Table 41 Middle East & Africa Tachycardia Market, By Type, 2020β2027, (USD Million)
Table 42 Middle East & Africa Tachycardia Market, By Treatment, 2020β2027, (USD Million)
Table 43 Middle East & Africa Tachycardia Market, By Diagnosis, 2020β2027, (USD Million)
Table 44 Middle East & Africa Tachycardia Market, By End-User, 2020β2027, (USD Million)β
LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation For Global Tachycardia Market
Figure 3 Segmentation Market Dynamics For Tachycardia Market
Figure 4 Global Tachycardia Market Share, By Type 2020
Figure 5 Global Tachycardia Market Share, By Treatment 2020
Figure 6 Global Tachycardia Market Share, By End-User, 2020
Figure 7 Global Tachycardia Market Share, By Region, 2020
Figure 8 North America Tachycardia Market Share, By Country, 2020
Figure 9 Europe Tachycardia Market Share, By Country, 2020
Figure 10 Asia Pacific Tachycardia Market Share, By Country, 2020
Figure 11 Middle East & Africa Tachycardia Market Share, By Country, 2020
Figure 12 Global Tachycardia Market: Company Share Analysis, 2020 (%)
Figure 13 Abbott Laboratories: Key Financials
Figure 14 Abbott Laboratories: Segmental Revenue
Figure 16 Abbott Laboratories: Geographical Revenue
Figure 17 Terumo Corporation.: Key Financials
Figure 18 Terumo Corporation: Segmental Revenue
Figure 19 Terumo Corporation: Geographical Revenue
Figure 20 Medtronic PLC: Key Financials
Figure 21 Medtronic PLC: Segmental Revenue
Figure 22 Medtronic PLC: Geographical Revenue
Figure 23 TZ Medical, Inc.: Key Financials
Figure 24 TZ Medical, Inc.: Segmental Revenue
Figure 25 TZ Medical, Inc.: Geographical Revenue
Figure 26 GlaxoSmithKline Plc: Key Financials
Figure 27 GlaxoSmithKline Plc: Segmental Revenue
Figure 28 GlaxoSmithKline Plc. Geographical Revenue
Figure 29 Essential Medical, Inc.: Key Financials
Figure 30 Essential Medical, Inc.: Segmental Revenue
Figure 31 Essential Medical, Inc.: Geographical Revenue
The global tachycardia market is segmented on the basis of type, treatment, diagnosis, and end-user.
On the basis of type, the market is segmented into atrial fibrillation, atrial flutter, supraventricular tachycardia, ventricular tachycardia, ventricular fibrillation, and tachy-brady syndrome.
On the basis of treatment, the market is segmented into vagal maneuvers, medications, and cardioversion. On the basis of diagnosis, the market is segmented into imaging tests, electrocardiogram, and stress test. On the basis of imaging tests, it is further sub-segmented into echocardiogram, MRI, CT scan, coronary angiogram, and chest X-ray.
On the basis of end-user, the market is segmented into ambulatory surgical centers, specialty centers, and hospitals and clinics.
Figure: Global Tachycardia Market, by Region, 2016 (%)
Source: World Health Organization, Centers for Disease Control and Prevention, expert interview, annual report, white paper, company presentation and market research future analysis
Tachycardia Market Regional Analysis
The North American tachycardia market is a growing market in the Americas region. On a regional basis, the Americas region is segmented into North America and South America. North America is segmented into the U.S. and Canada. The increasing number of alcohol consumption and rising prevalence of cardiovascular rates are likely to enhance the growth of vascular closure devices. Additionally, the increasing need for minimally invasive procedures, growing healthcare expenditure, and the rising demand for technologically advanced treatments and products along with the rising government support are likely to enhance the growth of the tachycardia market in North America.
Europe is the second largest market and holds a healthy share in the global tachycardia market. The European market is expected to grow during the forecast period owing to the availability of newer and advanced treatment facilities and healthcare expenditure along with growing need for better healthcare infrastructure. Furthermore, increasing cardiovascular rates, along with rising population inclined towards sedentary lifestyle is driving the growth of the tachycardia market. According to the European Heart Network, in 2015, there were 11.3 million cardiovascular disorder cases in Europe.
Asia Pacific is expected to be the fastest growing market. The increasing prevalence of chronic diseases is the major driver for the market growth. China is the fastest growing region owing to an increasing population. The increasing awareness about health and availability of new treatment methods drives the market in this region. The increasing healthcare expenditure and rise in the standard of living are driving the growth of the tachycardia market in the Asia Pacific region.
The Middle East and Africa is expected to show the least growth in the market due to some major factors such as lack of awareness and limited access and availability of treatment facilities. In the Middle East, the United Arab Emirates is the largest market owing to the development of the healthcare industry and rising availability of specialty care centers.
Tachycardia Market Key Players
Some of the key players in the Tachycardia market are TZ Medical, Cardiva Medical Inc., Medtronic plc, Terumo Corporation Essential Medical, Inc., Merit Medical Systems, Inc., Abbott, Cardinal Health Inc., Inc., and Vasorum Ltd.
Research Methodology
Source: World Health Organization, Centers for Disease Control and Prevention, expert interview, annual report, white paper, company presentation and market research future analysis
Intended Audience
Report Attribute/Metric | Details |
---|---|
Market Size | Significant Value |
CAGR | 2018-2023: Substantial CAGR |
Base Year | 2019 |
Forecast Period | 2027 |
Historical Data | 2018 |
Forecast Units | Value (USD Million) |
Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
Segments Covered | Type, Treatment, Diagnosis, And End-User |
Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
Key Vendors | TZ Medical, Cardiva Medical Inc., Medtronic plc, Terumo Corporation Essential Medical, Inc., Merit Medical Systems, Inc., Abbott, Cardinal Health Inc., Inc., and Vasorum Ltd. |
Key Market Opportunities | Increasing approvals for vascular closure devices and government initiatives |
Key Market Drivers |
|
Frequently Asked Questions (FAQ) :
Tachycardia is a common type of heart disorder, which results in a faster heartbeat.Β
Tachycardia Market is expected to exhibit a strong 6.5% CAGR over the forecast period till 2023.
growing prevalence of cardiovascular disorders is the major driver for the Tachycardia Market.
Americas hold a dominant 48% share in the global tachycardia market.
Leading players in the Tachycardia Market include TZ Medical, Vasorum Ltd., and Medtronic, among others.